Impact of Nutritional Status and Body Composition on Osimertinib Tolerance in Non

Abstract

Get full access to this article

View all access options for this article.

References

Pilikidou

Palyvou

Papadopoulou

, et al. Lung cancer, treatment and nutritional status. Mol Clin Oncol. 2021;15:248. doi:10.3892/mco.2021.2410

Barca-Díez

Palmeiro-Carballa

Castro-Luaces

, et al. Nutritional status and its impact on treatment tolerance in non-small-cell lung cancer patients receiving osimertinib. Nutrients. 2025;17:927. doi:10.3390/nu17050927

Rinninella

Cintoni

Raoul

, et al. Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. Intern Emerg Med. 2021;16(5):1341-1356. doi:10.1007/s11739-020-02623-7

Chen

Herzberg

Henick

, et al. Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer. Oncologist. 2025;30(8):oyae315. doi:10.1093/oncolo/oyae315

Impact of Nutritional Status and Body Composition on Osimertinib Tolerance in Non–Small-Cell Lung Cancer

Abstract

Get full access to this article

References